ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > Angiogenin

Angiogenin

概要

Name:Cleavage and polyadenylation specificity factor subunit 3
Target Synonym:YSH1,Cleavage And Polyadenylation Specificity Factor 73 KDa Subunit,Cleavage And Polyadenylation Specific Factor 3, 73kD Subunit,CPSF 73 KDa Subunit,NEDMHSN,NEDMHS,EC 3.1.27,Cleavage and polyadenylation specificity factor 73 kDa subunit (CPSF 73 kDa subunit),mRNA 3 -end-processing endonuclease CPSF-73,CPSF73,Cleavage And Polyadenylation Specific Factor 3,CPSF-73,Cleavage And Polyadenylation Specificity Factor Subunit 3,Cleavage And Polyadenylation Specific Factor 3, 73kDa,MRNA 3 -End-Processing
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:2
Lastest Research Phase:Phase 1 Clinical

製品リスト製品比較と製品注文

製品仕様別:
製品カテゴリー別:
種類別:
タグ別:
コンジュゲート:
製造番号 種類 製品説明 構造 純度 特徴
ANN-H5149 Human Human Angiogenin / RNASE5 Protein, His Tag
ANN-H5149-structure
ANN-H5149-sds
ACRO Quality

生物活性データの一部

ANN-H5149-ELISA
 Angiogenin SPR

Human Angiogenin, His Tag (Cat. No. ANN-H5149) immobilized on CM5 Chip can bind Human Plexin B2, His Tag (Cat. No. PL2-H52H3) with an affinity constant of 17.5 nM as determined in a SPR assay (Biacore 8K) (QC tested).

Synonym Name

ALS9,ANG,Angiogenin,angiogenin, ribonuclease, RNase A family, 5,EC 3.1.27,EC:3.1.27.-

Background

Binds to actin on the surface of endothelial cells; once bound, angiogenin is endocytosed and translocated to the nucleus. Stimulates ribosomal RNA synthesis including that containing the initiation site sequences of 45S rRNA. Cleaves tRNA within anticodon loops to produce tRNA-derived stress-induced fragments (tiRNAs) which inhibit protein synthesis and triggers the assembly of stress granules (SGs). Angiogenin induces vascularization of normal and malignant tissues. Angiogenic activity is regulated by interaction with RNH1 in vivo

Clinical and Translational Updates

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
DNDI-6148 DNDI-6148 Phase 1 Clinical Drugs For Neglected Diseases Initiative Infections; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral Details
AN-3661 AN-6426; AN-3661 Phase 1 Clinical Anacor Pharmaceuticals Inc Malaria Details
DNDI-6148 DNDI-6148 Phase 1 Clinical Drugs For Neglected Diseases Initiative Infections; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral Details
AN-3661 AN-6426; AN-3661 Phase 1 Clinical Anacor Pharmaceuticals Inc Malaria Details

This web search service is supported by Google Inc.

totopphone